Making the DARPin Difference Reality for Patients

Transcription

1 Making the DARPin Difference Reality for Patients Corporate Presentation of Molecular Partners AG, Switzerland (SIX: MOLN) January 22 nd Molecular Partners AG Slide 1

2 Molecular Partners: Who We Are $ Teamwork Swiss biotech 120 team members Discovery to Phase 2 (POC) Science & patients first DARPin Therapies High patient value DARPin Difference Abicipar in Phase 3 (ophtha) MP0250 in Phase 2 (onc) MP0274 in Phase 1 (onc) Broad preclin. I/O portfolio Long-term Partnerships Alliance with Allergan Swiss listing (MOLN) Cash CHF 152mn* Financed well beyond key value inflection points DARPin Platform DARPin Difference: unlock novel modes of action Proof of Platform in the eye and systemically Fast and cost effective drug discovery engine *As of Sep 30, I/O, immuno-oncology Molecular Partners AG Slide 2

3 Investment Case and Key Messages Successful transition from DARPin platform into clinical product company Key value inflection points ahead: MP0250 (2x Phase 2) and MP0274 (Phase 1) in oncology Abicipar (Phase 3 data) in ophthalmology MP0310 selected as 1 st development candidate from our I/O DARPin toolbox Financed beyond 2019, capturing key value inflection points Keep on forward integrating towards late-stage development and the market DARPin is a registered trademark owned by Molecular Partners AG Molecular Partners AG Slide 3

4 Technology Platform DARPin Proteins: A Different Class of Therapeutics Derived from ankyrin repeat proteins which are naturally occurring binding proteins in multifunctional contexts Drug discovery engine Mono-DARPin are selected to a target from large DARPin libraries Fast and cost-effective Ideal properties Mono-DARPin MP0250: mixture in one Flexible architecture Multi-DARPin candidates: Linked mono-darpin domains ( 6 so far) Different linkers short, long, flexibel, rigid, Small size, high potency, high stability, high affinity, high developability Proof of platform Low immunogenicity and long t 1/2 in bloodstream (14 days) and eye MP0274: handcuff Multi-DARPin MP0310: Tumor-site Switch DARPin Difference Collections of 10,000 multi-darpin candidates are screened for new MoA Allosteric modulation Local agonists 2018 Molecular Partners AG Slide 4

5 Technology Platform A Differentiated Platform to Fill the Pipeline DARPin Difference Identify unique product candidate Patient Need Define target(s) Screen for desired phenotype Apoptosis Activation via clustering etc. Mono-DARPin library (>10 12 ) Build multi-darpin library (>10,000 multi-darpin combinations) Select highly diverse mono-darpin proteins to various epitopes 2018 Molecular Partners AG Slide 5

6 DARPin Engine: Unlimited Source of Candidates I/O Ophthalmology Oncology Pipeline Balanced and Robust Portfolio Discovery Preclinical Phase 1 Phase 2 Phase 3 MP0250 in MM MP0250 in EGFR-mut NSCLC MP0274: HER2+ patients MP0310: 4-1BB-FAP multi-darpin Multiple discovery programs Abicipar in wet AMD Abicipar in DME Two DARPin candidates Multiple discovery programs Partnership AMD, age-related macular degeneration; DME, diabetic macular edema; MM, multiple myeloma; NSCLC, non-small cell lung cancer Molecular Partners AG Slide 6

7 Pipeline Turning the DARPin Differentiation into Patient Outcome Our Target Profiles Preclinical Phase 1 Phase 2 Phase 3 MP0310 MP0274 MP0250 Abicipar NSCLC Wet AMD MM Tumor-restricted activity (switch) to avoid doselimiting side effects Molecular handcuff inducing cell death in HER2+ cancer cells Blocking 2 key escape pathways in parallel Long-acting VEGF inhibitor in the eye Opening a new therapeutic window for combinations Activity in patients no longer benefiting from approved antibodies Restore activity of drugs to which cancer has become resistant in MM and NSCLC Noninferiority to competition with less frequent ocular injections 2018 Molecular Partners AG Slide 7

8 Value Pipeline Ready to Capture Value Beyond Ophthalmology Oncology Value in our proprietary oncology pipeline Ophthalmology Value in ophthalmology with our partner Allergan Time 2018 Molecular Partners AG Slide 8

9 Oncology MP0250: A First-in-Class Bi-Specific DARPin Molecule MP0250 First bi-specific biologic blocking VEGF and HGF VEGF and HGF/c-MET are key escape pathways to SOC treatments This escape has been described for liquid and solid tumors Blocking the escape pathways may restore activity of SOC drugs Our choice of indications Multiple myeloma (MM) EGFR-mutated non-small cell lung cancer (NSCLC) Potential in additional indications HGF DARPin VEGF DARPin HSA DARPin Fully owned by Molecular Partners IP protection at least until 2036 SOC, standard of care; HSA, human serum albumin Molecular Partners AG Slide 9

10 Oncology MP0250 Blocks Two Tumor Escape Pathways Untreated Upregulation of escape pathways after SOC SOC + MP0250 MP0250 VEGF VEGF VEGF Tumor pathways HGF (c-met) HGF (c-met) HGF (c-met) MP Molecular Partners AG Slide 10

11 Tumor Volume (mm 3 ) Combined HGF and VEGF Inhibition Leads to Synergistic Effect in Mouse Model Oncology Tumor Growth Inhibition Syngeneic colorectal cancer model* (MC38) MP Vehicle Anti-HGF Anti-VEGF Anti-VEGF & Anti-HGF MP Treatment (days) *Syngeneic model: HGF c-met axis fully functional murine tumor grown in mouse strain of origin Molecular Partners AG Slide 11

12 Relative Tumor Volume (%) Oncology MP0250 can be Combined with Many Agents Across Different Tumors to Increase Their Potency MP0250 Gastric cancer PDX model GXA3027 Head & neck cancer PDX model HNXF1905 Pancreatic cancer tumor model KP V e h ic le V e h ic le V e h ic le M P M P M P P a c lita x e l M P p a c lita x e l C is p la tin M P c is p la tin G e m c ita b in e M P g e m c ita b in e PDX model, patient-derived xenograft mouse model Treatment (days) Molecular Partners AG Slide 12

13 Oncology MP0250 Can Be Dosed Safely, Conveniently and Shows Clear Signs of Efficacy in Phase 1 Study MP0250 Dosing* Convenient, flexible administration Exposure Repeated dosing resulted in good exposure Safety Well tolerated Efficacy Clear signs of antitumor efficacy Infusion well tolerated Dosing every 2 or 3 weeks possible Systemic half-life: ~2 weeks Sustained drug exposure throughout treatment periods (max. to (max. date to >12 date months) >12 mo) Only 1/40 patients developed a relevant titer of ADAs (>10 fold above background) Most common AE was hypertension, generally well controlled with standard medication: AEs were as expected AEs were as expected for VEGF inhibitor for a VEGF inhibitor 2 patients showed significant reduction in tumor volume Treatment duration was 3 mo in 18 patients (40%) and 6 mo in 4 patients (10%) These first-in-human data support the development of DARPin therapy via systemic administration. * 1- and 3-h infusion q2wk at doses 8 mg/kg or q3wk at 12 mg/kg; 1- and 3-h infusion well tolerated. ADA, anti-drug antibody; AE, adverse event. Study details can be found at clinicaltrials.gov/nct Molecular Partners AG Slide 13

14 Biological rationale Oncology Our Indications for Phase 2: MM and NSCLC MP0250 Multiple myeloma Head & neck squamous-cell EGFR-mutated NSCLC Nasopharyngeal HCC Colorectal cancer Anal cancer Feasibility of internal clinical development* Bubble size indicates estimated relative market potential (incidences). Source: Datamonitor. *Based on internal assessment on speed to market and complexity of development program. Potential of gastric, renal and other cancers under evaluation Molecular Partners AG Slide 14

15 p-c-met p-c-met HGF & VEGF Rationale in MM is Supported by Clinical Data Bone marrow of 8 MM patients sampled for HGF expression levels: HGF score 3+ Oncology Patients 6/8 HGF receptor activation 1 dynamics Newly diagnosed 40% On partial remission 28% 2% MP /8 Resistant SOC Relapsed 92% 89% 1+ 0/8 3% 7% c-met c-met VEGF rationale: A small MM study of bevacizumab (Avastin ) + bortezomib (Velcade ) demonstrated benefit over Velcade alone 2 1. Moschetta M, et al. Clin Cancer Res 2013;19: ; 2. White D, et al. Cancer 2013;119: Molecular Partners AG Slide 15

16 Oncology MP0250 Combination with Velcade Results in Superior Efficacy in Mouse Model MP0250 Vehicle Velcade MP0250 Velcade + MP0250 Bone morphology Muscle invasion by tumor Xenograft model H Molecular Partners AG Slide 16

17 Oncology Unique Potential of MP0250 in MM MP0250 Multiple myeloma is the 2 nd most common blood cancer Global market value ~USD 9bn, expected to reach >12bn by 2021 (6% CAGR) * 75% 25% 1 st /2 nd -line n= >100,000* HGF/ c-met IMiD or PI + mab Transplant PI or IMiD + mab No later-line treatments target these key escape pathways 3 rd /4 th -line n= ~30,000* PI IMiD or X Y + MP0250 MP0250: Potential to become backbone for all later lines *Including US/5EU/JP. Datamonitor Molecular Partners AG Slide 17

18 Oncology MP0250 Phase 2 Study in MM MP0250 RRMM n=6 Part 1: Dose Escalation Velcade /dexamethasone MP mg/kg q3wk Velcade /dexamethasone Part 2: Dose Expansion n=28 MP0250 target dose Endpoints: ORR, PFS n=6 MP mg/kg q3wk Phase 2 open-label, single-arm, multicenter study of MP Velcade + dexamethasone in patients with refractory and relapsed multiple myeloma (RRMM) Study population: MM patients who have received 2 lines of therapy, including Velcade and an IMiD, and have shown no response to most recent therapy or progressed 60 days after most recent therapy Study status*: 8 patients have been treated in the first dose escalation cohort (MP0250, 8 mg/kg) Next readout: Initial efficacy 2018 *Data cutoff 4th January 2018 Study details can be found at clinicaltrials.gov/nct Molecular Partners AG Slide 18

19 Urinary M Protein MP0250 Phase 2 Study in MM Initial Safety Read-out: Combination Well Tolerated Study status*: Initial dose level: 8mg/kg/3weeks No dose-limiting toxicities have been reported at data cutoff 8 RRMM patients were dosed, with 7 evaluable for safety and efficacy determination at data cutoff Preliminary Results 4 of 7 patients have evidence of anti-myeloma activity 3 patients with Partial Response (PR) 1 patient with Minimal Response (MR) *Data cutoff: 4th January 2018 **Kappa Free Light Chain measurement in line with M-protein Study details can be found at clinicaltrials.gov/nct Oncology MR (50 89%) PR ( 90%) Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5 Cycle 6 Cycle 7 Week 0 Week 6 Week 12 Week Molecular Partners AG Slide 19 Urinary M Protein % Change over Time: Patient X, MP mg/kg + Vd** -73% -83% -93% MP0250

20 Tumor Volume (mm 3 ) Oncology HGF & VEGF Rationale in NSCLC is Supported by Preclinical & Clinical Data MP Preclinical Rationale MP0250 in Lung Cancer Model Treatment (days) Vehicle Tarceva MP0250 MP Tarceva HGF Rationale Clinical Rationale Activation of MET pathway appears to be significantly involved in acquired resistance to TKI HGF/c-MET pathway is most frequently observed non-egfr related resistance mechanism to TKI 1 Savolitinib (c-met TKI) + osimertinib (Tagrisso ) produced 28% response in patients who failed Tagrisso and showed MET amplification; c-met amplification (15%) is a subgroup of HGF/c-MET upregulation (60 80%) 2 VEGF Rationale Efficacy of VEGF (anti-angiogenesis) already clinically proven: Avastin studies 3-4 TKI, tyrosine kinase inhibitor. 1. Chabon JJ, et al. Nat Commun 2016; 2. Spigel R, et al. J Clin Onc 2017; 3. Sandler A, et al. N Engl J Med 2006; 4. Reck M, et al. J Clin Oncol Molecular Partners AG Slide 20

21 Oncology Unique Potential of MP0250 in EGFR mut NSCLC MP0250 Treatment Line Current Treatment Future Treatment 1 st -line 1 st gen TKI n=200, nd -line 3 rd gen TKI n=130,000 1 Refractory n=70,000 1 HGF/c-MET Iressa or Tarceva Tagrisso Tagrisso No targeted drugs approved Our Phase 2 Study: MP0250 Tagrisso + 1 st -line 2 nd -line HGF/c-MET MP Tagrisso NSCLC is leading cause of cancer death Activating EGFR mutations are found in up to 10% of Western and up to 50% of Asian NSCLC 1 Global market value (EGFR NSCLC) ~USD 1.9bn, expected to reach >2.5bn by 2021 (7% CAGR) 1 1. Including US/5EU/JP. Datamonitor Molecular Partners AG Slide 21

22 Oncology MP0250 Phase 2 Study in NCSLC MP0250 EGFR mut NSCLC after Tagrisso n=6 Part 1: Dose Escalation Tagrisso MP mg/kg q3wk Tagrisso Part 2: Dose Expansion n=34 MP0250 target dose Endpoints: ORR, PFS n=6 MP mg/kg q3wk Status: FDA approval Sep st oncology DARPin drug candidate in US On track to dose 1 st patient in Q Next readouts: initial safety in 2018 & initial efficacy 2019 *The study details can be found on clinicaltrials.gov when available Molecular Partners AG Slide 22

23 Oncology MP0274: Killing HER2+ Cells with New MoA Allosteric inhibitor of HER2 blocks HER2- and HER3-mediated signaling and induces apoptosis Current antibody-based treatments do not cure advanced HER2+ tumors Our new MoA may help patients not adequately responding to current therapies Ongoing Phase 1 in HER2 positive tumor patients progressing on SOC HSA DARPin HER2 DARPin B MP0274 HER2 DARPin A Fully owned by Molecular Partners IP protection until at least Molecular Partners AG Slide 23

24 % Killing Oncology MP0274 is a Highly Potent Tumor Cell Killer Tumor Cell Apoptosis BT474 MP Tumor Cell Killing BT474 MP0274 Ado-trastuzumab emtansine (Kadcyla ) MP [nm] Trastuzumab/ Pertuzumab (Herceptin / Perjeta ) New MoA may help patients who do not adequately respond to current therapies [nm] 2018 Molecular Partners AG Slide 24

25 Oncology Direct Induction of Tumor Cell Death with MP0274 «Open» MP0274 «Locked» MP0274 HER1 HER2 HER3 Apoptosis Effector-cell independent tumor cell death Natural Killer Cell HER2 signals tumor cell survival & proliferation ADCC Effector-cell mediated tumor cell death Herceptin & Perjeta ADCC, antibody-dependent cellular cytotoxicity Molecular Partners AG Slide 25

26 Oncology MP0274: Phase 1 Study in HER2+ Cancer Patients Phase 1, first-in-human, single-arm, multicenter, open-label, repeated-dose, dose escalation study to assess safety, tolerability and pharmacokinetics of MP0274 in patients with advanced HER2-positive solid tumors with expansion cohort at recommended dose to confirm safety and to assess preliminary efficacy Primary objective: to assess the safety and tolerability of MP0274 in patients with HER2-positive solid tumors who have progressed after standard therapy for advanced disease Study treatment: Dose Escalation (Part A): 4 dose groups (4x 3 6 patients), starting dose 4 mg/kg q3wk Dose Expansion (Part B): at recommended dose: 26 patients (total of up to 32 patients at target dose) Status: 3 sites open for recruitment (Germany, Switzerland, UK); 1 st patients dosed; 2 additional sites planned for dose expansion Next readouts: initial safety data expected 1 st half of 2018; initial efficacy data towards end of 2018 MP0274 Value proposition: completely new mode of action: induction of apoptosis in HER2-addicted cancer cells independent of ADCC compared with approved therapies *Study details can be found at clinicaltrials.gov/nct Molecular Partners AG Slide 26

27 activate Responders activate activate Many Different Combination Approaches Needed to Capture Full Market Potential KILL T-Cell Engagers T-cell ACTIVATE Costimulatory Targets BLOCK Checkpoint Targets Tumor Cell Block Block + Activate Kill Kill + Kill + Kill + Activate Block Block + Activate 2018 Molecular Partners AG Slide 27

28 I/O Toxicity Limits Full Potential of Antibody Agonists IN CIRCULATION (SYSTEMIC) IN CIRCULATION (SYSTEMIC) Clustering: activation of T-cells everywhere in body IN THE TUMOR IN THE TUMOR Activated T-cell Cell Activated T-cell Tumor Cell No Clustering = no effect Tumor Stroma Clustering: T-cell activation Stimulator SWITCH Localizer 2018 Molecular Partners AG Slide 28

29 Our Vision: Expand the Therapeutic Window, Enabling Combinations to Become Successful I/O Toxicity Efficacy 2018 Molecular Partners AG Slide 29

30 Localizer I/O DARPin Toolbox with Unlimited Combinations Switch Stimulator OX BB a CD40 c A B FAP MP0310 C D Many DARPin candidates are under investigation for both solid and liquid tumors (including combinations) 2018 Molecular Partners AG Slide 30

31 Luminescence Signal Luminescence Signal I/O All Successful DARPin Stimulators to Date ,0 0 0 OX BB Link A, et al. EACR Abstr , , , , , , , , , DARPin Concentration (nm) 2018 Molecular Partners AG Slide CD OFF ON OFF Without Clustering With Clustering SWITCH

32 I/O MP0310: Activating T-cells (only) in the Tumor Tumor-restricted T-cell co-stimulator MP0310 Local activation of immune cells No systemic side effects expected Ideal combination partner for other T-cell based therapies HSA DARPin FAP DARPin Many FAP-positive cancers could benefit from T-cell activation 4-1BB DARPin Fully owned by Molecular Partners IP protection at least until 2038 FAP, fibroblast activation protein Molecular Partners AG Slide 32

33 Animals (n) Relative Tumor Volume (%) I/O Overview of MP0310 Data MP0310 No systemic toxicity Ideal for combinations Vehicle MP Control Antibody MP0310 Body weight loss >10% 1/10 8/10 1/10 MP0310 shows lower systemic toxicity compared with current therapy Days Mono A Combo * Would be ideal combination partner with other drugs *p<0.001, 2-way ANOVA Molecular Partners AG Slide 33

34 Abicipar Retinal Diseases: Unmet Medical Needs Remain Wet AMD and DME are leading causes of blindness in Western world Large and rapidly growing group driven by aging population Current standard of care is Lucentis or Eylea Both require monthly intravitreal injections Significant unmet medical need for less frequent injections and doctor office visits 2018 Molecular Partners AG Slide 34

35 Abicipar Abicipar: Most Advanced DARPin Therapy Abicipar Long-acting PEGylated mono-darpin protein blocking VEGF Potentially transformative therapy with less frequent ocular injections compared with standard of care Phase 2 data suggest quarterly dosing and comparable efficacy to Lucentis Drug Safety Monitoring Committee (DSMC): no changes recommended anti-vegf DARPin Wet AMD Phase 3 read out: 1 year data in 2018 Allergan plans to start DME Phase 3 in Molecular Partners AG Slide 35

36 CAGR: 18% Abicipar Opportunities in the Wet AMD and DME Market Global Wet AMD and DME Market Size (USDbn) 1 * Abicipar Other USD 8bn annual sales (2016) and growing (wet AMD and DME) SOC: Eylea and Lucentis : bi-monthly or monthly injections Aflibercept (Eylea ) Ranibizumab (Lucentis ) Global license agreement with Allergan all development costs borne by Allergan Up to $360mn open milestones & low double-digit to mid-teen tiered royalties Reported by EvaluatePharma, a service of Evaluate Ltd. (UK), Accessed 27 Apr *Avastin is used off label Molecular Partners AG Slide 36

37 BCVA (letters ± SE) Abicipar Phase 2 Data Suggest Quarterly Dosing for Wet AMD Dosing Change of Best-Corrected Visual Acuity (BCVA)* Abicipar 2.0 mg Abicipar 1.0 mg Lucentis 0.5 mg Week Safety Data Vision Gain (letters) Safety (n/n) Wk 16 Wk 20 AEs / / /16 Abicipar The abicipar formulation has been further optimized for safety for use in Phase 3. Allergan, 12 August *Study not powered to reach statistical significance; Ocular inflammation. SE, standard error Molecular Partners AG Slide 37

38 CEDAR and SEQUOIA: Abicipar Registration Studies in Wet AMD Abicipar 2 mg q12w Abicipar 2 mg q8w Lucentis 0.5 mg q4w 2 parallel, randomized, double-blind phase 3 studies 2x 900 patients globally Loading Doses Patient recruitment completed since early May 2017 (4 months ahead of plan) Drug Safety Monitoring Committee (DSMC): no changes recommended Abicipar Primary Endpoint Next milestones: 1 year read-out in 2018 (triggers FDA filing), targeted launch in 2020 Extension Week Abicipar 2018 Molecular Partners AG Slide 38

39 Abicipar Abicipar: One of Allergan s Star Programs Abicipar Allergan: Q earnings call (May 9 th ) & Leerink Partner conference (Feb 15 th ) Molecular Partners AG Slide 39

40 Multiple Value Inflection Points Ahead Abicipar Wet AMD: 1-y Ph 3 efficacy DME: Ph 3 expected start Wet AMD: expected launch MP0250 MM: initial efficacy NSCLC: initial safety MM: efficacy NSCLC: initial efficacy NSCLC: efficacy MP0274 Initial safety Initial efficacy Efficacy MP0310 Preclinical data FIH Funding beyond Molecular Partners AG Slide 40

41 Appendix 2018 Molecular Partners AG Slide 41

42 Appendix Experienced Management Team Dr. Patrick Amstutz, CEO Co-founder, former CBO & COO PhD in molecular biology from UZH Dr. Andreas Harstrick, CMO, MD 28 years of experience in oncology, including Erbitux development Brought four mab oncology products to market Senior executive roles at Merck-Serono, Imclone, Eli Lilly Dr. Michael Stumpp, CSO Co-founder PhD and postdoc from UZH; research in Tokyo, London Andreas Emmenegger, CFO Joined 2007 as CFO and first investor Former CFO Glycart and Head Strategic Alliance Genentech at Roche >20 years experience as CFO of private & listed companies; raised >$0.5bn, including two IPOs 2018 Molecular Partners AG Slide 42

43 Appendix Experienced and Independent Board of Directors Jörn Aldag (Chairman) CEO, Hookipa Biotech AG Former CEO, uniqure and Evotec Steven H. Holtzman President and CEO, Decibel Therapeutics Former EVP, Biogen Göran Ando Chairman, Novo Nordisk Former CSO, Pharmacia William Bill Lee EVP Research, Gilead Jeffrey H. Buchalter Former CEO, Enzon and Ilex Oncology Senior roles at Pharmacia, Wyeth, Schering-Plough Andreas Plückthun Professor, UZH Co-founder, Morphosys Gwen Fyfe Former VP, Oncology Development at Genentech Petri Vainio Managing Director, Essex Woodlands Ventures Patrick Amstutz Co-founder, CEO Molecular Partners Bill Burns (Vice Chairman) Former CEO of Roche Pharmaceuticals Former board member of Roche, Genentech, Chugai Pharmaceuticals 2018 Molecular Partners AG Slide 43

44 Appendix Financial Summary 1H 2017 (CHF million; as per IFRS) H H change Revenues (7.5) Total expenses 1 (22.7) (22.0) (0.7) Operating loss EBIT (16.7) (8.5) (8.2) Net finance expenses (2.7) (1.2) (1.5) Net loss (19.4) (9.7) (9.7) Net cash used in operations (20.5) (17.5) (3.0) Cash balance , (39.4) Financial Guidance for Full-Year Total expenses of ~ CHF 50 million, of which ~ CHF 5 million non-cash effective costs Capital expenditures of ~ CHF 2 million on top No guidance on net cash flow; timelines and potential milestone payments with partnerships not disclosed Guidance subject to progress and changes in pipeline 1 Thereof non-cash costs of CHF 2.6 million in H and CHF 2.5 million in H Including CHF 38.3 million short-term time deposits (H1 2016: CHF 19.6 million). 3 Cash balance per September 30, 2017: CHF million. 3 Update of financial guidance with Interim Management Statement of October 27, Molecular Partners AG Slide 44

45 Appendix Shareholder Structure As of June 30, 2017 Highlights 53% 26% 21% Listed on SIX Swiss Exchange (ticker symbol: MOLN) Included in key indices: SPI, SPI Extra, SXI Life Sciences and SXI Bio+Medtech 20,794,606 shares outstanding CHF 610 million market cap. as of June 30, 2017 Pre-IPO investors (5 VCs) Management, Board, Founders Others No lock-up restrictions in place Formal free float as per SIX definition: 74% 2018 Molecular Partners AG Slide 45

46 Mean Change in BCVA (letters ± SE) Phase 2 Data Showing Long Duration of Action in DME Appendix Abicipar Primary Loading Doses Endpoint Vision gain (letters) Safety Week Abicipar 2 mg q12w Abicipar 2 mg q8w Abicipar 1 mg q8w Lucentis 0.5 mg q4w Wk 28 AEs (n/n) 7.2 4/ / / / Lucentis 0.5 mg q4w Abicipar 2 mg q12w Week The abicipar formulation has been further optimized for safety for use in Phase Molecular Partners AG Slide 46

47 Appendix IR Agenda Date Event February 08, 2018 Unaudited Financial Results 2017 March 16, 2018 Expected Publication of Annual Report 2017 April 18, 2018 Annual General Meeting for Business Year Molecular Partners AG Slide 47

48 Appendix Disclaimer This presentation is not an offer to sell or a solicitation of offers to purchase or subscribe for shares of Molecular Partners AG, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decision. This presentation is not an offering circular within the meaning of Article 652a of the Swiss Code of Obligations, nor is it a listing prospectus as defined in the listing rules of the SIX Swiss Exchange AG or a prospectus under any other applicable laws. Copies of this presentation may not be sent to countries, or distributed in or sent from countries, in which this is barred or prohibited by law. This document is not a prospectus or a prospectus equivalent document and investors should not subscribe for or purchase any securities referred to in this document. This document does not constitute a recommendation regarding the shares. This presentation contains specific forward-looking statements, beliefs or opinions, including statements with respect to the product pipelines, potential benefits of product candidates and objectives, estimated market sizes and opportunities as well as the milestone potential under existing collaboration agreements, which are based on current beliefs, expectations and projections about future events, e.g. statements including terms like potential, believe, assume, expect, forecast, project, may, could, might, will or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of Molecular Partners AG and investments and those explicitly or implicitly presumed in these statements. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these statements and forecasts. Past performance of Molecular Partners AG cannot be relied on as a guide to future performance. Forward-looking statements speak only as of the date of this presentation and Molecular Partners AG, its directors, officers, employees, agents, counsel and advisers expressly disclaim any obligations or undertaking to release any update of, or revisions to, any forward looking statements in this presentation. No statement in this document or any related materials or given at this presentation is intended as a profit forecast or a profit estimate and no statement in this document or any related materials or given at this presentation should be interpreted to mean that earnings per share for the current or future financial periods would necessarily match or exceed historical published earnings per share. As a result, you are cautioned not to place any undue reliance on such forward-looking statements. Unless stated otherwise the information provided in this presentation are based on company information. This presentation is intended to provide a general overview of Molecular Partners AG s business and does not purport to deal with all aspects and details regarding Molecular Partners AG. Accordingly, neither Molecular Partners AG nor any of its directors, officers, employees, agents, counsel or advisers nor any other person makes any representation or warranty, express or implied, as to, and accordingly no reliance should be placed on, the accuracy or completeness of the information contained in the presentation or of the views given or implied. Neither Molecular Partners AG nor any of its directors, officers, employees, agents, counsel or advisers nor any other person shall have any liability whatsoever for any errors or omissions or any loss howsoever arising, directly or indirectly, from any use of this information or its contents or otherwise arising in connection therewith. The material contained in this presentation reflects current legislation and the business and financial affairs of Molecular Partners AG which are subject to change and audit Molecular Partners AG Slide 48

49 Molecular Partners AG Wagistrasse Zürich-Schlieren Switzerland T Molecular Partners AG Slide 49